Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Gilead Sciences develops HIV integrase inhibitors

Oct. 26, 2016

Merck & Co. patents HIV integrase inhibitors

Oct. 11, 2016

Gilead opens phase II/III study of fixed-dose combination in young patients with HIV-1 infection

Oct. 7, 2016

Selexis expands collaboration with IAVI

Sep. 23, 2016

Aphios obtains funding from NIAID to develop cure for HIV/AIDS

Sep. 15, 2016

Janssen-Cilag submits MAA to EMA for darunavir-based single tablet regimen

Sep. 13, 2016

New York Blood Center patents anti-HIV antibody-drug conjugates

Sep. 8, 2016

European Commission grants marketing authorization to Gilead's Truvada

Aug. 23, 2016

Viiv Healthcare starts phase III trial for two-drug regimen of dolutegravir/lamivudine

Aug. 18, 2016

Genmab and Gilead Sciences enter DuoBody license agreement

Aug. 11, 2016

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...